Form 13-F position report

CYTOKINETICS INC

Reported by Mirador Capital Partners LP

CYTK CUSIP 23282W605 Manager CIK 0001633446

Reported 208,896 shares, up 6,526 (3.2%) from the prior quarter.

Reported value -20.1%; share count 3.2% vs. the prior quarter.

Added
% of reported 13F value 1.6% This manager · Q3 2026
Shares 208,896 Quarter-end amount reported
Reported value $13,768,359 Fair value at quarter end
Consecutive quarters held 28 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 6956000
2022-03-31 5871000
2022-06-30 6427000
2022-09-30 6225000
2022-12-31 2691100
2023-03-31 1991191
2023-06-30 1752934
2023-09-30 1638801
2023-12-31 4087002
2024-03-31 2485750
2024-06-30 3421088
2024-09-30 3412253
2024-12-31 3087517
2025-03-31 3983834
2025-06-30 4769225
2025-09-30 10847290
2025-12-31 12616375
2026-03-31 13358177
2026-06-30 17239900
2026-09-30 13768359

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for CYTOKINETICS INC held by Mirador Capital Partners LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Added 208,896 +6,526 (3.2%) 1.6% $13,768,359 2026-10-09
Q2 2026 Reduced 202,370 -303 (-0.1%) 2.11% $17,239,900 2026-07-07
Q1 2026 Added 202,673 +4,115 (2.1%) 1.89% $13,358,177 2026-04-08
Q4 2025 Added 198,558 +1,191 (0.6%) 1.73% $12,616,375 2026-01-14
Q3 2025 Added 197,367 +53,020 (36.7%) 1.54% $10,847,290 2025-10-07
Q2 2025 Added 144,347 +45,222 (45.6%) 0.77% $4,769,225 2025-07-09
Q1 2025 Added 99,125 +33,489 (51.0%) 0.7% $3,983,834 2025-04-09
Q4 2024 Added 65,636 +1,010 (1.6%) 0.56% $3,087,517 2025-01-15
Q3 2024 Added 64,626 +1,483 (2.3%) 0.61% $3,412,253 2024-10-04
Q2 2024 Added 63,143 +27,688 (78.1%) 0.64% $3,421,088 2024-07-12
Q1 2024 Reduced 35,455 -13,497 (-27.6%) 0.47% $2,485,750 2024-04-18
Q4 2023 Reduced 48,952 -6,676 (-12.0%) 0.87% $4,087,002 2024-01-19
Q3 2023 Added 55,628 +1,890 (3.5%) 0.37% $1,638,801 2023-10-05
Q2 2023 Reduced 53,738 -2,846 (-5.0%) 0.42% $1,752,934 2023-08-14
Q1 2023 Reduced 56,584 -2,148 (-3.7%) 0.47% $1,991,191 2023-04-14
Q4 2022 Reduced 58,732 -69,753 (-54.3%) 0.64% $2,691,100 2023-02-10
Q3 2022 Reduced 128,485 -35,098 (-21.5%) 1.5% $6,225,000 2022-11-14
Q2 2022 Added 163,583 +4,085 (2.6%) 1.52% $6,427,000 2022-08-05
Q1 2022 Added 159,498 +6,879 (4.5%) 1.19% $5,871,000 2022-05-06
Q4 2021 Reduced 152,619 -10,857 (-6.6%) 1.46% $6,956,000 2022-02-02
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

540 managers reported CYTOKINETICS INC for Q3 2026.

Managers reporting CYTOKINETICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Added 21,041,152 +946,790 0.02% $1,386,822,344 9 qtrs
T Rowe Price Investment Management Inc Added 18,912,704 +194,206 0.88% $1,246,537,000 16 qtrs
WELLINGTON MANAGEMENT GROUP LLP Added 10,590,381 +3,658,611 0.12% $698,012,012 26 qtrs
STATE STREET CORPORATION Added 7,143,229 +648,996 0.01% $470,810,223 54 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 6,799,536 +87,737 0.02% $448,157,418 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 6,266,419 +148,904 < 0.01% $413,019,676 3 qtrs
Avoro Capital Advisors LLC Reduced 4,900,000 -99,999 3.33% $322,959,000 3 qtrs
Bank of America Corporation Added 4,735,328 +99,619 0.02% $312,105,470 53 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 3,767,864 +55,363 0.01% $248,385,218 54 qtrs
Polar Capital Holdings Plc Added 9,635,314 +7,381,665 0.55% $227,685,323 24 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
October 09, 2026
Filing type
13F-HR
Position type
COM NEW

Voting authority reported

Sole
208,896
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.